Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABCL NASDAQ:ETNB NASDAQ:NVTS NASDAQ:VIGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$5.11+1.8%$3.32$1.89▼$5.82$1.50B0.626.89 million shs5.17 million shsETNB89BIO$9.59-3.9%$9.99$4.16▼$11.84$1.46B1.281.47 million shs1.18 million shsNVTSNavitas Semiconductor$8.79-2.1%$6.25$1.52▼$9.48$1.72B3.0127.21 million shs21.83 million shsVIGLVigil Neuroscience$8.05$7.51$1.31▼$8.10$383.88M3.34691,068 shs465,973 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics+0.60%+28.72%+36.41%+95.33%+66.78%ETNB89BIO-0.99%-6.29%+1.73%+43.80%+10.89%NVTSNavitas Semiconductor+1.81%+43.22%+22.18%+338.05%+127.34%VIGLVigil Neuroscience-0.25%-0.37%+1.51%+349.72%+89.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABCLAbCellera Biologics2.2306 of 5 stars3.51.00.00.02.63.30.0ETNB89BIO1.8629 of 5 stars3.51.00.00.02.50.80.6NVTSNavitas Semiconductor0.9843 of 5 stars1.32.00.00.02.03.30.6VIGLVigil Neuroscience3.9363 of 5 stars4.05.00.00.03.32.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCLAbCellera Biologics 3.00Buy$8.7571.23% UpsideETNB89BIO 3.00Buy$26.43175.58% UpsideNVTSNavitas Semiconductor 2.50Moderate Buy$3.71-57.81% DownsideVIGLVigil Neuroscience 2.00Hold$10.8034.16% UpsideCurrent Analyst Ratings BreakdownLatest VIGL, NVTS, ABCL, and ETNB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025ABCLAbCellera BiologicsKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$5.00 ➝ $10.007/12/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)7/7/2025ABCLAbCellera BiologicsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/7/2025ABCLAbCellera BiologicsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$5.006/27/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)6/17/2025NVTSNavitas SemiconductorDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$3.506/11/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/28/2025VIGLVigil NeuroscienceStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$11.00 ➝ $8.005/27/2025VIGLVigil NeuroscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$14.00 ➝ $8.005/24/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/23/2025VIGLVigil NeuroscienceMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCLAbCellera Biologics$23.11M65.98N/AN/A$3.58 per share1.43ETNB89BION/AN/AN/AN/A$3.34 per shareN/ANVTSNavitas Semiconductor$83.30M20.24N/AN/A$1.85 per share4.75VIGLVigil NeuroscienceN/AN/AN/AN/A$1.75 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCLAbCellera Biologics-$162.86M-$0.56N/AN/AN/A-737.56%-15.98%-12.38%8/7/2025 (Estimated)ETNB89BIO-$367.08M-$3.38N/AN/AN/AN/A-81.44%-70.17%8/4/2025 (Estimated)NVTSNavitas Semiconductor-$84.60M-$0.52N/AN/AN/A-131.83%-22.62%-20.38%8/4/2025 (Estimated)VIGLVigil Neuroscience-$84.26M-$2.05N/AN/AN/AN/A-111.70%-74.67%8/12/2025 (Estimated)Latest VIGL, NVTS, ABCL, and ETNB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025VIGLVigil Neuroscience-$0.44N/AN/AN/AN/AN/A8/7/2025Q2 2025ABCLAbCellera Biologics-$0.17N/AN/AN/A$7.55 millionN/A8/4/2025Q2 2025ETNB89BIO-$0.49N/AN/AN/AN/AN/A8/4/2025Q2 2025NVTSNavitas Semiconductor-$0.05N/AN/AN/A$14.43 millionN/A5/8/2025Q1 2025ABCLAbCellera Biologics-$0.17-$0.15+$0.02-$0.15$7.12 million$4.24 million5/7/2025Q1 2025VIGLVigil Neuroscience-$0.53-$0.49+$0.04-$0.49N/AN/A5/5/2025Q1 2025NVTSNavitas Semiconductor-$0.06-$0.06N/A-$0.09$14.01 million$14.02 million5/1/2025Q1 2025ETNB89BIO-$0.50-$0.49+$0.01-$0.49N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCLAbCellera BiologicsN/AN/AN/AN/AN/AETNB89BION/AN/AN/AN/AN/ANVTSNavitas SemiconductorN/AN/AN/AN/AN/AVIGLVigil NeuroscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCLAbCellera BiologicsN/A10.1510.15ETNB89BIO0.0618.0318.03NVTSNavitas SemiconductorN/A5.614.78VIGLVigil NeuroscienceN/A2.972.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCLAbCellera Biologics61.42%ETNB89BION/ANVTSNavitas Semiconductor46.14%VIGLVigil Neuroscience83.64%Insider OwnershipCompanyInsider OwnershipABCLAbCellera Biologics28.90%ETNB89BIO2.60%NVTSNavitas Semiconductor29.90%VIGLVigil Neuroscience18.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCLAbCellera Biologics500298.42 million212.18 millionOptionableETNB89BIO40145.98 million142.19 millionOptionableNVTSNavitas Semiconductor160191.81 million134.46 millionOptionableVIGLVigil Neuroscience4047.69 million39.10 millionNot OptionableVIGL, NVTS, ABCL, and ETNB HeadlinesRecent News About These CompaniesVigil Neuroscience, Inc. (NASDAQ:VIGL) Given Consensus Recommendation of "Hold" by AnalystsJuly 17, 2025 | americanbankingnews.comVIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGLJuly 14, 2025 | businesswire.comVigil Neuroscience, Inc. (NASDAQ:VIGL) Receives Consensus Recommendation of "Hold" from BrokeragesJuly 12, 2025 | marketbeat.comVigil Neuroscience (NASDAQ:VIGL) Stock Price Up 0.4% - Here's What HappenedJuly 9, 2025 | marketbeat.comVigil Neuroscience, Inc. (VIGL) Cash Flow - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comWall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High? - NasdaqJune 27, 2025 | nasdaq.comWall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High?June 25, 2025 | zacks.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of ShareholdersJune 9, 2025 | prnewswire.comWall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a BetJune 9, 2025 | zacks.comVigil Neuroscience halts Phase 2 trial for ALSP treatmentJune 5, 2025 | investing.comVigil’s TREM2 Antibody for Rare Brain Disease Flunks Phase II TrialJune 5, 2025 | biospace.comBVIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors ...June 5, 2025 | morningstar.comMDisappointing results see Vigil Neuro drop iluzanebart developmentJune 4, 2025 | thepharmaletter.comTVIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the FirmJune 4, 2025 | prnewswire.comVigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSPJune 4, 2025 | globenewswire.comShould You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?June 2, 2025 | zacks.comStifel cuts Vigil Neuroscience stock rating, lowers target to $8May 29, 2025 | investing.comStifel Downgrades Vigil Neuroscience (VIGL)May 29, 2025 | msn.comHC Wainwright & Co. Downgrades Vigil Neuroscience (VIGL)May 28, 2025 | msn.comVigil Neuroscience Analyst Ratings and Price Targets | NASDAQ:VIGL | BenzingaMay 24, 2025 | benzinga.comVIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil ...May 24, 2025 | morningstar.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVIGL, NVTS, ABCL, and ETNB Company DescriptionsAbCellera Biologics NASDAQ:ABCL$5.11 +0.09 (+1.79%) Closing price 04:00 PM EasternExtended Trading$5.13 +0.02 (+0.39%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.89BIO NASDAQ:ETNB$9.59 -0.39 (-3.91%) Closing price 04:00 PM EasternExtended Trading$9.68 +0.09 (+0.94%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Navitas Semiconductor NASDAQ:NVTS$8.79 -0.19 (-2.12%) Closing price 04:00 PM EasternExtended Trading$8.78 -0.01 (-0.17%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Navitas Semiconductor Corporation designs, develops, and markets gallium nitride power integrated circuits, silicon carbide, associated high-speed silicon system controllers, and digital isolators used in power conversion and charging. The company's products are used in mobile, consumer, data center, solar, electric vehicle, industrial motor drive, smart grid, and transportation applications. It operates in the United States, Europe, China, rest of Asia, and internationally. The company was founded in 2013 and is based in Torrance, California.Vigil Neuroscience NASDAQ:VIGL$8.05 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$8.02 -0.04 (-0.43%) As of 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
